: +31 (0) 317 453 908
: info@check-points.com

Home | About Us | Company News | Introducing the Check-MDR CT103
"It provided definitive results within the same working day, allowing rapid implementation of isolation measures and appropriate antibiotic treatment"

Naas et al.

Antimicrobial Agents and Chemotherapy, 2010

Introducing the Check-MDR CT103

Published on: Jun 08, 2011

The Check-MDR CT103 combines the resistance markers included in the Check-MDR CT101 and Check-MDR CT102 into a single test. In addition, new markers have been added which enable the distinction between two commonly encountered ESBLs: CTX-M-1 and CTX-M-15.

By simultaneously identifying the clinically prevalent carbapenemases, ESBLs and AmpCs, Check-MDR CT103 enables you to take the first step towards control.

Learn more

Back to news list


newsletter

Thank you for your interest!

The Check-Points newsletter helps you to stay updated on the the latest developments in gram negative antibiotic resistance.

Sent on a quarterly basis, the newsletter features the latest news from Check-Points as well as summaries of key publications in the field and links to relevant news stories. Special issues will appear for ICAAC and ECCMID.

Subscribe below: